イリノイ州における大うつ病性障害の臨床試験
イリノイ州内の拠点で、大うつ病性障害に関する20件の研究が参加者を募集しています。
イリノイ州内の都市
公式研究テキスト（英語）
A Study of Brenipatide (LY3537031) in Adult Participants With Major Depressive Disorder
- Charter Research - Chicago, Chicago
被験者募集中第3相
18歳〜75歳 · 全性別 · 2026/10/01更新 · NCT07775300A Study of Seltorexant as Monotherapy in Adults and Elderly Participants With Major Depressive Disorder
- Chicago Research Center, Chicago
被験者募集中第3相
18歳〜74歳 · 全性別 · 2026/10/01更新 · NCT07573176Phase 3 Study of Adjunctive Treatment With Seltorexant in Adult and Elderly Participants With Major Depressive Disorder and Insomnia Symptoms
- Northwestern University, Chicago
- Baber Research Group, Naperville
被験者募集中第3相
18歳〜74歳 · 全性別 · 2026/09/25更新 · NCT06559306A Study to Evaluate TNX-102 SL Monotherapy Versus Placebo in Participants With Major Depressive Disorder (MDD)
- Chicago Research Center, Chicago
被験者募集中第2相
18歳以上 · 全性別 · 2026/09/25更新 · NCT07621237A Study to Evaluate the Efficacy and Safety of Esketamine for Reduction of Symptoms of Major Depressive Disorder
- Endeavor Health Evanston Hospital, Evanston
被験者募集中第3相
12歳〜17歳 · 全性別 · 2026/09/25更新 · NCT07227454A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder
- Rush University, Chicago
被験者募集中第3相
18歳〜85歳 · 全性別 · 2026/09/25更新 · NCT06793397Evaluation of Efficacy and Safety of Milsaperidone as Adjunctive Therapy in Patients With Major Depressive Disorder
- Vanda Investigational Site, Chicago
被験者募集中第3相
18歳〜65歳 · 全性別 · 2026/09/24更新 · NCT06830044A Study to Evaluate the Effectiveness of Valbenazine in Adult Participants With Tardive Dyskinesia (TD) Who Remain Symptomatic While Receiving or After Stopping a Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor
- Neurocrine Clinical Site, Naperville
被験者募集中第4相
18歳以上 · 全性別 · 2026/09/18更新 · NCT07105111A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder (X-NOVA3)
- Advanced Quality Medical Research, Orland Park
被験者募集中第3相
18歳〜74歳 · 全性別 · 2026/09/08更新 · NCT07076407A Study to Evaluate the Effectiveness of DT-101 as an Adjunctive Treatment in Patients With Depression
- Draig Clinical Site, Chicago
- Draig Clinical Site, Skokie
被験者募集中第2相
18歳〜75歳 · 全性別 · 2026/09/02更新 · NCT07610473Treatment ResistAnt Depression Subcallosal CingulatE Network DBS (TRANSCEND)
- Rush University Medical Center, Chicago
被験者募集中
22歳〜70歳 · 全性別 · 2026/08/28更新 · NCT06423430A Phase 3 Trial of DT120 for Major Depressive Disorder (Ascend)
- Uptown Research Institute, Chicago
被験者募集中第3相
18歳〜74歳 · 全性別 · 2026/08/10更新 · NCT07592689A Phase 2 Study of Zelquistinel or Placebo for the Reduction of Symptoms of Major Depressive Disorder
- EmVenio Research, Chicago
被験者募集中第2相
18歳〜64歳 · 全性別 · 2026/07/27更新 · NCT07115329Clinical Assessment of Response in the Treatment of Depression With Daytime Sleepiness Using Solriamfetol
- Clinical Research Site, Chicago
被験者募集中第3相
18歳〜65歳 · 全性別 · 2026/07/24更新 · NCT07484217A Study to Assess Change in Disease Activity and Adverse Events of Oral Icalcaprant in Adult Participants With Major Depressive Disorder
- Flourish Research - Great Lakes Clinical Trials /ID# 278201, Chicago
- Amr Conventions Research /ID# 277547, Warrenville
被験者募集中第2相
18歳〜65歳 · 全性別 · 2026/06/15更新 · NCT07276997Exercise Training for Managing Major Depressive Disorder in Multiple Sclerosis
- University of Illinois at Chicago, Chicago
被験者募集中
18歳〜64歳 · 全性別 · 2026/06/04更新 · NCT05051618A Study to Assess the Efficacy, Safety and Tolerability of VLS-01 Buccal Film, Compared to Placebo in Patients With Treatment Resistant Depression (ELUMINA)
- Pillar Clinical Research LLC, Chicago
被験者募集中第2相
18歳〜65歳 · 全性別 · 2026/05/11更新 · NCT06524830Biomarkers/Biotypes, Course of Early Psychosis and Specialty Services
- University of Chicago Medical Center, Chicago
被験者募集中観察研究
18歳〜40歳 · 全性別 · 2026/03/10更新 · NCT06740383A Study to Evaluate the Efficacy of AXS-05 Compared to Bupropion in Preventing the Relapse of Depressive Symptoms
- Clinical Research Site, Chicago
被験者募集中第4相
18歳〜65歳 · 全性別 · 2025/01/23更新 · NCT06223880ClinicalTrials.govより、2026/10/05時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。